Welcome! Login | Register
 

5 Ways to Simplify Meal Preparation—5 Ways to Simplify Meal Preparation

Smart Benefits: New FMLA Spouse Definition Now In Effect—On February 25, the Department of Labor issued…

Sharks Roll Falcons 4-1, Win 5th Straight—Sharks beat Falcons 4-1

College Admissions: 5 Admission Factors You Can’t Predict—As the last few colleges release admission decisions…

Sharks Edge IceCaps 3-2 in OT—Sharks win 4th straight, beat IceCaps 3-2 in…

Monfredo: Worcester - The City That Reads - 10th Annual Book Drive and The Goal is 32,000 Books—The kick off for the tenth annual book…

Leonard Moorehead, The Urban Gardener: Spring Poised on the Equinox—Start having fun in the garden

Rowe Lifts Revs To First Win Of 2015—Behind two goals from Kelyn Rowe, the New…

Fit for Life: The Ride of Your Life…—Are you willing to accept everything the way…

Sharks Net Six Goals, Beat Falcons 6-3—The Worcester Sharks (35-23-4-2) defeated the (34-26-7-0) Springfield…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.